Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Sebastian Ohlendorff

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Annals of Epidemiology|April 10, 2025
The next generation of regression standardization with the R package stdReg2Michael C Sachs, Johan Sebastian Ohlendorff, Adam Brand, et al.
Clinical Trials (London, England)|June 2, 2026
Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trialKathrine Kold Sørensen, Johan Sebastian Ohlendorff, Anders Munch, et al.
Diabetes, Obesity & Metabolism|February 25, 2026
Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetesKathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, et al.
Cardiovascular Diabetology|October 7, 2025
Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetesKathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, et al.
Cardiovascular Diabetology|October 1, 2025
Type 2 diabetes, sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: real world evidence versus a randomised clinical trialPuriya Daniel Würtz Yazdanfard, Kathrine Kold Sørensen, Bochra Zareini, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Annals of Epidemiology|April 10, 2025
The next generation of regression standardization with the R package stdReg2Michael C Sachs, Johan Sebastian Ohlendorff, Adam Brand, et al.
Clinical Trials (London, England)|June 2, 2026
Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trialKathrine Kold Sørensen, Johan Sebastian Ohlendorff, Anders Munch, et al.
Diabetes, Obesity & Metabolism|February 25, 2026
Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetesKathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, et al.
Cardiovascular Diabetology|October 7, 2025
Real-world cardiovascular effectiveness of sustained glucagon-like peptide 1 GLP-1 receptor agonist usage in type 2 diabetesKathrine Kold Sørensen, Puriya Daniel Würtz Yazdanfard, Bochra Zareini, et al.
Cardiovascular Diabetology|October 1, 2025
Type 2 diabetes, sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: real world evidence versus a randomised clinical trialPuriya Daniel Würtz Yazdanfard, Kathrine Kold Sørensen, Bochra Zareini, et al.
Pageof 1